Guardian Pharmacy Services, Inc. (GRDN) 股票分析

公司概述

Guardian Pharmacy Services, Inc. operates as a pharmacy service company dedicated to delivering a comprehensive suite of technology-enabled services to long-term health care facility (LTCF) residents across the United States, focusing on individualized clinical care, drug dispensing, and administration capabilities. The company functions within the Healthcare sector, specifically categorized under the Medical Care Facilities industry, positioning it as a specialized provider in the broader healthcare infrastructure rather than direct patient care delivery. With a market capitalization of $2.62B and annual revenue of $1.45B, the firm manages a workforce of 3,600 employees, indicating a substantial operational footprint within the specialized pharmacy management space. These valuation and revenue figures suggest that the market assigns significant value to the company's established network and its critical role in supporting the pharmaceutical needs of long-term care institutions, reflecting a stable yet capital-intensive business model.

财务健康

The company reported a revenue of $1.45B over the trailing twelve months, with a net income of $49.22M and an EBITDA of $102.62M. The substantial gap between the $1.45B in revenue and the $49.22M in net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, consume approximately 96.6% of top-line revenue before interest and taxes. Free cash flow stands at $73.88M, which provides the company with essential financial flexibility to cover capital expenditures, service debt obligations, or pursue strategic acquisitions without immediate reliance on external financing. The gross margin is recorded at 20.2%, while the operating margin is 8.9% and the profit margin is 3.4%, indicating that for every dollar of revenue, only a small fraction translates to bottom-line profit after all operational costs are deducted. On the balance sheet, the company holds $65.62M in cash against $44.72M in total debt, supported by a debt-to-equity ratio of 20.52, suggesting a leveraged position where debt obligations are significant relative to shareholders' equity. Liquidity is assessed via a current ratio of 1.38, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable buffer above the one-to-one threshold. Return on Equity is 26.6% and Return on Assets is 13.7%, metrics that demonstrate management's effectiveness in generating substantial returns for shareholders relative to the capital invested and the total asset base employed.

估值评估

The trailing twelve-month P/E ratio is 52.12, whereas the forward P/E ratio is 30.02, implying that the market expects a significant expansion in earnings per share over the coming year to justify the high current valuation multiple. The price-to-book ratio stands at 12.51, indicating that the market values the company at a substantial premium of more than twelve times its net asset book value, reflecting investor confidence in its intangible assets and future cash generation potential. Alternative valuation metrics such as the price-to-sales ratio of 1.81 and the EV/EBITDA of 25.00 provide context that the company is trading at a premium relative to both its sales revenue and its earnings before interest, taxes, depreciation, and amortization. The 52-week high is $40.73 and the 52-week low is $19.17; assuming a current price context within this historical range, the stock price has experienced notable volatility over the past year, though the exact current price percentage relative to the high cannot be calculated without the specific current share price data point provided in the facts. The beta value is not available in the provided data, preventing a quantitative assessment of the stock's price volatility relative to the broader market movements.

Growth & Income

Revenue growth year-over-year is recorded at 17.4%, while earnings growth year-over-year is listed as N/A, meaning that while top-line expansion is robust, the specific year-over-year change in net income is not disclosed in the available financial data. In the absence of reported earnings growth figures, it is difficult to determine if earnings are expanding faster or slower than revenue, but the high revenue growth rate suggests a strong top-line trajectory that management aims to convert into profitability. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm retains all of its earnings to reinvest into business operations, technology upgrades, and expansion rather than distributing cash to shareholders. This reinvestment strategy aligns with the capital-intensive nature of the pharmacy services industry, where growth is typically funded internally or through debt rather than through share buybacks or dividend distributions.